Lijing Pharmaceutical: Profit attributable to shareholders increases 125.59% YoY in 2025, proposes 10-for-2 split with 6 yuan dividend

MetaMuskRat · 2026-03-24T12:30:25+00:00

Renmin Finance News, March 24: Lisheng Pharma (002393) released its annual report on March 24. In 2025, the company achieved operating revenue of 1.392 billion yuan, an increase of 4.18% year-over-year; net profit attributable to parent company shareholders was 416 million yuan, an increase of 125.59% year-over-year; basic earnings per share was 1.62 yuan. The company plans to distribute 2 bonus shares for every 10 shares held and pay a cash dividend of 6 yuan per share (inclusive of tax).

MetaMuskRat

2026-03-24 12:30:25

人民财讯3月24日电，力生制药(002393)3月24日发布年度报告，2025年实现营业收入13.92亿元，同比增长4.18%；归母净利润为4.16亿元，同比增长125.59%；基本每股收益1.62元。公司拟每10股转增2股并派发现金红利6元（含税）。

Voir l'original

Cette page peut inclure du contenu de tiers fourni à des fins d'information uniquement. Gate ne garantit ni l'exactitude ni la validité de ces contenus, n’endosse pas les opinions exprimées, et ne fournit aucun conseil financier ou professionnel à travers ces informations. Voir la section Avertissement pour plus de détails.